Olesoxime Report issue

Small molecule Experimental
AACT ChEMBL DrugBank MeSH PubChem

Active Ingredient History

NOW
  • Now

Chemistry

  • SMILES: CC(C)CCC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=NO)CC[C@]4(C)[C@H]3CC[C@]12C
  • InChIKey: QNTASHOAVRSLMD-GYKMGIIDSA-N
  • Mol. Mass: 399.66
  • ALogP: 7.86
  • ChEMBL Molecule:
    olesoxime  
More Chemistry

Pharmacology

  • Mechanism of Action:
  • Multi-specific: Missing data
  • Black Box: No
  • Availability: Missing data
  • Delivery Methods: Missing data
  • Pro Drug: No

Alternative names

cholest-4-en-3-one, oxime | olesoxime | tro19622 | tro-19622

Organizations (17)

Research & Development (17)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (0)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (11)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (11)


 

Amyotrophic Lateral Sclerosis (Phase 2/Phase 3)

Colorectal Neoplasms (Phase 1/Phase 2)

Diabetic Neuropathies (Phase 2)

Drug-Related Side Effects and Adverse Reactions (Phase 2)

Healthy Volunteers (Phase 1)

Multiple Sclerosis, Relapsing-Remitting (Phase 1)

Muscular Atrophy, Spinal (Phase 2)

Non-alcoholic Fatty Liver Disease (Phase 2)

Shock (Phase 2/Phase 3)

Spinal Diseases (Phase 2)

Spinal Muscular Atrophies of Childhood (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 16
  • # of Trial Organizations: 17

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue